MK-6240
Sponsors
Abbvie Deutschland GmbH & Co. KG, Biogen Idec Research Limited, Washington University School Of Medicine, Sanofi-Aventis Recherche & Developpement, University of Southern California
Conditions
Alzheimer DiseaseAlzheimer Disease, Early OnsetAlzheimer's disease (AD)DementiaDementia Alzheimer's typeDominantly Inherited Alzheimer Disease (DIAD)Mild Cognitive ImpairmentMild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disease Dementia
Phase 1
Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
WithdrawnCTIS2022-501644-15-00
Target: 327Updated: 2023-02-20
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease
CompletedCTIS2022-500691-59-00
End: 2024-06-27Target: 98Updated: 2024-06-03
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD)
Active, not recruitingCTIS2024-515198-91-00
Start: 2022-12-20Target: 24Updated: 2025-07-04
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.
Not yet recruitingCTIS2025-524581-14-00
Target: 213Updated: 2026-08-18